{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:35:12Z","timestamp":1791959712095,"version":"4.3.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ekir.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T02:13:03Z","timestamp":1631844783000},"page":"2942-2957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["The Crystalline Nephropathies"],"prefix":"10.1016","volume":"6","author":[{"given":"Mark A.","family":"Perazella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leal C.","family":"Herlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2021.09.003_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: an update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ekir.2021.09.003_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2021.09.003_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/ckj\/sfu105","article-title":"Crystalline-induced kidney disease: a case for urine microscopy","volume":"8","author":"Luciano","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2021.09.003_bib4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5858\/arpa.2011-0565-RA","article-title":"Crystalline nephropathies","volume":"136","author":"Herlitz","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib5","doi-asserted-by":"crossref","first-page":"292953","DOI":"10.1155\/2013\/292953","article-title":"Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators","volume":"2013","author":"Aggarwal","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000487671","article-title":"Novel insights into crystal-induced kidney injury","volume":"4","author":"Mulay","year":"2018","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2021.09.003_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ndt\/gft248","article-title":"Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease","volume":"29","author":"Mulay","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.2013.207","article-title":"NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy","volume":"84","author":"Knauf","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ebiom.2019.10.059","article-title":"H19 promote calcium oxalate nephrocalcinosis-induced renal tubular epithelial cell injury via a ceRNA pathway","volume":"50","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ekir.2021.09.003_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.kint.2016.03.035","article-title":"An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice","volume":"90","author":"Ludwig-Portugall","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/ndt\/gfy239","article-title":"Targeting kidney inflammation as a new therapy for primary hyperoxaluria?","volume":"34","author":"Martin-Higueras","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind common drug nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib13","first-page":"550","article-title":"Drug-induced acute kidney injury: diverse mechanisms of tubular injury","volume":"25","author":"Perazella","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ekir.2021.09.003_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2018.07.012","article-title":"Urine sediment examination in the diagnosis and management of kidney disease: core curriculum 2019","volume":"73","author":"Cavanaugh","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/nep.12428","article-title":"Sulfadiazine-induced crystal nephropathy: a new \u2018old\u2019 problem","volume":"20","author":"Slade","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2021.09.003_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1053\/j.semdp.2020.02.002","article-title":"A\u00a0diagnostician\u2019s field guide to crystalline nephropathies","volume":"37","author":"Nicholas Cossey","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ekir.2021.09.003_bib17","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/archinte.1990.00390220113023","article-title":"Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome","volume":"150","author":"Simon","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-008-0772-0","article-title":"Renal dysfunction during and after high-dose methotrexate","volume":"63","author":"Green","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ekir.2021.09.003_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy [published correction appears in Semin Nephrol. 2011;31:317]","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.ekir.2021.09.003_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2020.1846733","article-title":"Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients","volume":"62","author":"Medrano","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ekir.2021.09.003_bib22","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1053\/ajkd.2001.27732","article-title":"Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors","volume":"38","author":"Reilly","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","article-title":"Crystalluria and urinary tract abnormalities associated with indinavir","volume":"127","author":"Kopp","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2018.11.014","article-title":"Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy","volume":"4","author":"Soto","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2021.09.003_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.ackd.2018.12.001","article-title":"The changing face of human immunodeficiency virus-mediated kidney disease","volume":"26","author":"Sury","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ckj\/sfv015","article-title":"Atazanavir nephrotoxicity","volume":"8","author":"Hara","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2021.09.003_bib27","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2017.02.376","article-title":"Atazanavir-associated crystalline nephropathy","volume":"70","author":"Santoriello","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib28","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/jac\/dku304","article-title":"Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study","volume":"69","author":"Nishijima","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ekir.2021.09.003_bib29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/1871526519666190617154137","article-title":"Antiviral drugs and acute kidney injury (AKI)","volume":"19","author":"Leowattana","year":"2019","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.ekir.2021.09.003_bib30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ki.2010.496","article-title":"Acute kidney injury due to crystalluria following acute valacyclovir overdose","volume":"79","author":"Roberts","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib32","first-page":"169","article-title":"Triamterene-induced crystalluria and cylinduria: clinical and experimental studies","volume":"26","author":"Fairley","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0140-6736(83)91542-8","article-title":"Abnormal urinary sediment in patients on triamterene","volume":"1","author":"Fairley","year":"1983","journal-title":"Lancet"},{"issue":"suppl D","key":"10.1016\/j.ekir.2021.09.003_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jac\/18.SD.187","article-title":"Ciprofloxacin: an overview of adverse experiences","volume":"18","author":"Ball","year":"1986","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ekir.2021.09.003_bib35","first-page":"91","article-title":"Ciprofloxacin: review of potential toxicologic effects","volume":"82","author":"Schluter","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000238444","article-title":"Crystalluria and ciprofloxacin, influence of urinary pH and hydration","volume":"32","author":"Thorsteinsson","year":"1986","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ekir.2021.09.003_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002018-199513060-00004","article-title":"Tolerability of fluoroquinolone antibiotics. Past, present and future","volume":"13","author":"Ball","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.ekir.2021.09.003_bib38","series-title":"Ciprofloxacin, Product Monograph","author":"Schacht","year":"1986"},{"key":"10.1016\/j.ekir.2021.09.003_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000238577","article-title":"Tolerance of intravenously administered ciprofloxacin","volume":"34","author":"Thorsteinsson","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ekir.2021.09.003_bib40","first-page":"75","article-title":"Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature","volume":"32","author":"Hootkins","year":"1989","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib41","first-page":"438","article-title":"Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation","volume":"164","author":"Chopra","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ekir.2021.09.003_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/ajkd.1998.v31.pm9531191","article-title":"Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes","volume":"31","author":"Dharnidharka","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib43","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1093\/ndt\/gfl160","article-title":"Ciprofloxacin crystal nephropathy\u2014a \u2018new\u2019 cause of acute renal failure","volume":"21","author":"Sedlacek","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2007.05.014","article-title":"Ciprofloxacin crystal nephropathy","volume":"50","author":"Stratta","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nephro.2005.02.005","article-title":"[Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin]","volume":"1","author":"Montagnac","year":"2005","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.ekir.2021.09.003_bib46","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/ndt\/gfl320","article-title":"Ciprofloxacin crystalluria","volume":"21","author":"Fogazzi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2021.09.003_bib47","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/clinids\/10.Supplement_1.S141","article-title":"Specific toxicologic aspects of the quinolones","volume":"10","author":"Christ","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib48","first-page":"2022","article-title":"High incidence of amoxicillin-induced crystal nephropathy in patients receiving high dose of intravenous amoxicillin","volume":"9","author":"Garnier","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib49","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14328","article-title":"Amoxicillin-induced crystal nephropathy: a nationwide French pharmacovigilance databases study","volume":"86","author":"Thomas","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2021.09.003_bib50","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0009922820912214","article-title":"Amoxicillin-induced crystalline nephropathy presenting as ureteral obstruction","volume":"59","author":"Kleppe","year":"2020","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.ekir.2021.09.003_bib51","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/S0140-6736(14)62001-8","article-title":"Macroscopic amoxicillin crystalluria","volume":"385","author":"Hentzien","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2021.09.003_bib52","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ki.2013.446","article-title":"The case: a crystal-clear diagnosis: acute kidney injury in a patient with suspected meningoencephalitis. Diagnosis: amoxicillin-induced crystal nephropathy","volume":"86","author":"Rafat","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5414\/CNP59455","article-title":"Massive amoxycillin crystalluria causing anuric acute renal failure","volume":"59","author":"Labriola","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib55","first-page":"47","article-title":"Onconephrology: the intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ekir.2021.09.003_bib56","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00277-020-03971-1","article-title":"An update to the pathogenesis for monoclonal gammopathy of renal significance","volume":"99","author":"Zuo","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ekir.2021.09.003_bib57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MNH.0000000000000369","article-title":"The treatment of paraprotein-related kidney disease","volume":"26","author":"Hutchison","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2021.09.003_bib58","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.2215\/CJN.02960316","article-title":"Paraprotein-related kidney disease: attack of the killer M proteins","volume":"11","author":"Perazella","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00005792-200005000-00002","article-title":"Adult Fanconi syndrome secondary to light chain gammopathy: clinicopathologic heterogeneity and unusual features in 11 patients","volume":"79","author":"Messiaen","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2021.09.003_bib60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12882-020-01813-w","article-title":"Clinicopathological characteristics of light chain proximal tubulopathy in Korean patients and the diagnostic usefulness of immunohistochemical staining for immunoglobulin light chain","volume":"21","author":"Jung","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib61","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.2008.666","article-title":"Light chain proximal tubulopathy","volume":"76","author":"Herlitz","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib62","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/modpathol.2011.104","article-title":"The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation","volume":"24","author":"Larsen","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ekir.2021.09.003_bib63","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib64","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.1995.269","article-title":"Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi\u2019s syndrome","volume":"48","author":"Leboulleux","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib65","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ekir.2020.06.026","article-title":"Multiple myeloma-associated Ig light chain crystalline cast nephropathy","volume":"5","author":"Matsumura","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2021.09.003_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5414\/CN109770","article-title":"Coincidental crystalline light chain cast nephropathy, light chain proximal tubulopathy, and urine crystallopathy: a case report and review of the literature","volume":"93","author":"Lerner","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CN108424","article-title":"Light chain crystalline kidney disease: diagnostic urine microscopy as the \u201cliquid kidney biopsy.\u201d","volume":"82","author":"Luciano","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ekir.2016.08.005","article-title":"Lambda light chain crystalline cast nephropathy and proximal tubulopathy","volume":"1","author":"Gallan","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2021.09.003_bib69","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum","volume":"12","author":"Lin","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2014050509","article-title":"Crystalglobulin-induced nephropathy","volume":"26","author":"Gupta","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.xkme.2019.01.006","article-title":"Crystalglobulin-induced nephropathy and keratopathy [published correction appears in Kidney Med. 2020;2:94]","volume":"1","author":"D\u2019Costa","year":"2019","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib72","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12882-020-01818-5","article-title":"Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: a case report","volume":"21","author":"Gupta","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5414\/CN110163","article-title":"Concomitant monoclonal immunoglobulin deposition disease and crystalglobulin-induced nephropathy with a membranoproliferative pattern of glomerular injury","volume":"94","author":"Pichler Sekulic","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib74","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/ndt\/gfq129","article-title":"Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome","volume":"25","author":"El Hamel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.ki.5001524","article-title":"Dysproteinemia-related nephropathy associated with crystal-storing histiocytosis","volume":"70","author":"Stokes","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12105-011-0326-3","article-title":"Crystal-storing histiocytosis: report of a case, review of the literature (80 cases) and a proposed classification","volume":"6","author":"Dogan","year":"2012","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.ekir.2021.09.003_bib77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00277-008-0660-z","article-title":"Renal crystal storing histiocytosis in a patient with multiple myeloma","volume":"88","author":"Farooq","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ekir.2021.09.003_bib78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MOP.0000000000000462","article-title":"Nephropathic cystinosis: an update","volume":"29","author":"Veys","year":"2017","journal-title":"Curr Opin Pediatr"},{"issue":"suppl 4","key":"10.1016\/j.ekir.2021.09.003_bib79","doi-asserted-by":"crossref","first-page":"iv87","DOI":"10.1093\/ndt\/gfu090","article-title":"Nephropathic cystinosis: an international consensus document","volume":"29","author":"Emma","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2215\/CJN.01740407","article-title":"Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping","volume":"3","author":"Servais","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib81","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1681\/ASN.2019080774","article-title":"Chitotriosidase as a novel biomarker for therapeutic monitoring of nephropathic cystinosis","volume":"31","author":"Veys","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00467-018-3974-7","article-title":"Potential use of stem cells as a therapy for cystinosis","volume":"34","author":"Rocca","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib83","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00467-012-2329-z","article-title":"Hereditary causes of kidney stones and chronic kidney disease","volume":"28","author":"Edvardsson","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib84","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/ndt\/gfp711","article-title":"Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure","volume":"25","author":"Nasr","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.09.003_bib85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.ajkd.2015.10.023","article-title":"Kidney disease in adenine phosphoribosyltransferase deficiency","volume":"67","author":"Runolfsdottir","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.09.003_bib86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00247-016-3723-7","article-title":"Primary hyperoxaluria: spectrum of clinical and imaging findings","volume":"47","author":"Strauss","year":"2017","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.ekir.2021.09.003_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00240-018-1093-3","article-title":"Recent advances in the identification and management of inherited hyperoxalurias [published correction appears in Urolithiasis. 2020;48(1):93]","volume":"47","author":"Sas","year":"2019","journal-title":"Urolithiasis"},{"key":"10.1016\/j.ekir.2021.09.003_bib88","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00467-020-04817-8","article-title":"Novel therapeutic approaches for the primary hyperoxalurias","volume":"36","author":"Belostotsky","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib89","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2021.09.003_bib90","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria","volume":"28","author":"Liebow","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib91","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran. An RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib92","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MNH.0000000000000621","article-title":"Stiripentol identifies a therapeutic target to reduce oxaluria","volume":"29","author":"Letavernier","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2021.09.003_bib93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.kint.2019.06.011","article-title":"Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy","volume":"97","author":"Wyatt","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib94","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","article-title":"Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning","volume":"129","author":"Le Dudal","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2021.09.003_bib95","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","article-title":"Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient","volume":"35","author":"Kempf","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pcl.2018.09.003","article-title":"Update on Dent disease","volume":"66","author":"Ehlayel","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.ekir.2021.09.003_bib97","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.kint.2016.04.022","article-title":"Observations of a large Dent disease cohort","volume":"90","author":"Blanchard","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.09.003_bib98","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-010-1657-0","article-title":"Dent\u2019s disease: clinical features and molecular basis","volume":"26","author":"Clayerie-Mart\u00edn","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib99","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1111\/jcmm.14590","article-title":"Dent disease: a window into calcium and phosphate transport","volume":"23","author":"Anglani","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.ekir.2021.09.003_bib100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneph.2017.83","article-title":"The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2","volume":"13","author":"De Matteis","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2021.09.003_bib101","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.21391","article-title":"From Lowe syndrome to Dent Disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes","volume":"32","author":"Hichri","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ekir.2021.09.003_bib102","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/tra.12160","article-title":"The cellular and physiological functions of the Lowe syndrome protein OCRL1","volume":"15","author":"Mehta","year":"2014","journal-title":"Traffic"},{"key":"10.1016\/j.ekir.2021.09.003_bib103","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneph.2009.124","article-title":"Inherited cerebrorenal syndromes","volume":"5","author":"Schurman","year":"2009","journal-title":"Nat Rev Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921014212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921014212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:38:43Z","timestamp":1762832323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024921014212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2468024921014212"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2021.09.003","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Crystalline Nephropathies","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}